

A Pharmacokinetics Study of Proposed Bevacizumab Biosimilar MYL-1402O vs
EU-Bevacizumab and US-Bevacizumab

Journal of Cancer Research and Clinical Oncology

Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Abhijit Barve, Mudgal Kothekar,
Mark A. Socinski, Cornelius F. Waller

Corresponding author:

Cornelius F. Waller, MD

Department of Hematology, Oncology and Stem Cell Transplantation

University Medical Centre Freiburg and Faculty of Medicine

University of Freiburg

E-mail: cornelius.waller@uniklinik-freiburg.de

Online Resource 1. Patient disposition. ^aOther reasons included outside of body mass index range, illness, failed physical examination, alcohol use within 48 hours of admission, medication use within 14 days of admission, consumption of >20 cigarettes in the 2 days before admission, use of cannabinoids 1 week before admission, inability to read/write properly, and other. Subjects who dropped out or withdrew for any reason, without successfully completing all screening evaluations, were considered screening failures.

